ERBB2 and breast carcinoma: However, 68Ga-F(ab’)2-trastuzumab PET imaging failed to identify any tumours among four of the eight patients with metastatic HER2-positive breast cancer assessed, due to relatively high liver uptake and blood pool activity as well as potential competition with therapeutically administered trastuzumab [38].